186 related articles for article (PubMed ID: 8723457)
1. Ciprofloxacin pharmacokinetics in burn patients.
Garrelts JC; Jost G; Kowalsky SF; Krol GJ; Lettieri JT
Antimicrob Agents Chemother; 1996 May; 40(5):1153-6. PubMed ID: 8723457
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of ciprofloxacin in patients with major burns.
Lesne-Hulin A; Bourget P; Ravat F; Goudin C; Latarjet J
Eur J Clin Pharmacol; 1999 Sep; 55(7):515-9. PubMed ID: 10501821
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and burn eschar penetration of intravenous ciprofloxacin in patients with major thermal injuries.
Varela JE; Cohn SM; Brown M; Ward CG; Namias N; Spalding PB
J Antimicrob Chemother; 2000 Mar; 45(3):337-42. PubMed ID: 10702553
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of cefepime in patients with thermal burn injury.
Bonapace CR; White RL; Friedrich LV; Norcross ED; Bosso JA
Antimicrob Agents Chemother; 1999 Dec; 43(12):2848-54. PubMed ID: 10582870
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.
Shah A; Lettieri J; Blum R; Millikin S; Sica D; Heller AH
J Antimicrob Chemother; 1996 Jul; 38(1):103-16. PubMed ID: 8858462
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.
Schaefer HG; Stass H; Wedgwood J; Hampel B; Fischer C; Kuhlmann J; Schaad UB
Antimicrob Agents Chemother; 1996 Jan; 40(1):29-34. PubMed ID: 8787874
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
8. Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans.
Szałek E; Połom W; Karbownik A; Grabowski T; Konkołowicz A; Wolc A; Matuszewski M; Krajka K; Grześkowiak E
Pharmacol Rep; 2012; 64(3):673-9. PubMed ID: 22814020
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.
Forrest A; Nix DE; Ballow CH; Goss TF; Birmingham MC; Schentag JJ
Antimicrob Agents Chemother; 1993 May; 37(5):1073-81. PubMed ID: 8517694
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of ciprofloxacin in critically ill patients after the first intravenous administration of 400 mg.
Szałek E; Tomczak H; Kamińska A; Grabowski T; Smuszkiewicz P; Matysiak K; Wolc A; Kaczmarek Z; Grześkowiak E
Adv Med Sci; 2012; 57(2):217-23. PubMed ID: 22968336
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.
Rubio TT; Miles MV; Lettieri JT; Kuhn RJ; Echols RM; Church DA
Pediatr Infect Dis J; 1997 Jan; 16(1):112-7; discussion 123-6. PubMed ID: 9002120
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration.
Spooner AM; Deegan C; D'Arcy DM; Gowing CM; Donnelly MB; Corrigan OI
BMC Clin Pharmacol; 2011 Aug; 11():11. PubMed ID: 21816053
[TBL] [Abstract][Full Text] [Related]
13. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Wong FA; Corrado M
Antimicrob Agents Chemother; 1998 May; 42(5):1098-104. PubMed ID: 9593134
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of pharmacokinetics/ pharmacodynamics of ciprofloxacin between 400 mg intravenously every 8 h and 400 mg intravenously every 12 h in patients with gram negative bacilli bacteremia.
Saengsuwan P; Jaruratanasirikul S; Jullangkoon M; Aeinlang N
J Med Assoc Thai; 2010 Jul; 93(7):784-8. PubMed ID: 20649056
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center.
Fournier A; Goutelle S; Que YA; Eggimann P; Pantet O; Sadeghipour F; Voirol P; Csajka C
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914948
[TBL] [Abstract][Full Text] [Related]
16. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin.
Forrest A; Ballow CH; Nix DE; Birmingham MC; Schentag JJ
Antimicrob Agents Chemother; 1993 May; 37(5):1065-72. PubMed ID: 8517693
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance.
Conil JM; Georges B; Lavit M; Seguin T; Tack I; Samii K; Chabanon G; Houin G; Saivin S
Int J Clin Pharmacol Ther; 2007 Oct; 45(10):529-38. PubMed ID: 17966838
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of enrofloxacin and its active metabolite ciprofloxacin in ill cows.
Fu LX; Jiang ZG; Ding HZ; Liu YH
J Vet Pharmacol Ther; 2008 Jun; 31(3):240-5. PubMed ID: 18471145
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid.
Rao GS; Ramesh S; Ahmad AH; Tripathi HC; Sharma LD; Malik JK
Vet J; 2002 Jan; 163(1):85-93. PubMed ID: 11749141
[TBL] [Abstract][Full Text] [Related]
20. Intravenous pharmacokinetics of ciprofloxacin in goats.
García Ovando H; Gorla N; Poloni G; Trotti N; Prieto G; Errecalde C
Int J Antimicrob Agents; 2000 Jun; 15(1):77-9. PubMed ID: 10856681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
